Legal & General Group
SABS icon

Legal & General Group’s SAB Biotherapeutics SABS Stock Holding History

Legal & General Group’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.5K Buy
+4,223
New +$15.7K ﹤0.01% 3197

Other funds holding SABS

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Legal & General Group's SABS Position: Q2 2026 in Review

Legal & General Group opened a new position in SAB Biotherapeutics (SABS) in Q2 2026: 4,223 shares worth $16.5K. The stake represents ﹤0.01% of the portfolio and ranks #3197 among its holdings.

87 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

  • Legal & General Group held 4,223 shares of SAB Biotherapeutics worth $16.5K as of Q2 2026.
  • SAB Biotherapeutics was a new Legal & General Group position in Q2 2026.
  • SAB Biotherapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #3197 holding.
  • 87 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.